ABOUT
Our Members
Board of Directors
Staff
Sponsors
Contact Us
Issue Areas
COVID-19
Reducing Health Costs
Health Care Reform
Value
Real-World Evidence
Patient Engagement
Personalized Health
FDA Regulations
Resources
Member Resources
Meetings & Events
Newsroom
Letters & Comments
Job Bank
Education
Health Care Quality
Value Classroom
Patient-Focused Medical Product Development Series
Webinars
Blog
Membership
Our Members
Standards of Excellence
Join Us
Toggle navigation
letters & comments
Patient-Focused Drug Development Guidance: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making; Public Workshop
02/03/2020
Read More
Health and Human Services’ Transparency in Coverage Proposed Rule
01/30/2020
Read More
Medicare and State Healthcare Programs: Fraud and Abuse; Revisions To Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements
12/31/2019
Read More
Letter to CMS on Medicare Program; Modernizing and Clarifying the Physician Self-Referral Regulations
12/31/2019
Read More
NHC Comments on Patient-Focused Drug Development: Methods to Identify What Is Important to Patients; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders
12/18/2019
Read More
NHC Comments on Congressional Efforts to Address Drug Pricing
12/17/2019
Read More
Letter to Representatives DeGette & Upton on the “Cures 2.0” Initiative
12/16/2019
Read More
NHC Comments on Proposed Changes to ICER’s 2020 Framework
10/18/2019
Read More
NHC Comments on CY 2020 Revisions to Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment Policies
09/27/2019
Read More
« Previous
1
2
3
4
5
6
Next »
